Patent intelligence · US
US 7629168
Insulin expressing human pancreatic islet cell line capable of reversibly proliferating and use thereof
Insulin expressing human pancreatic islet cell line capable of reversibly proliferating and use thereof
Patent details — US 7629168
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 8, 2009
- Expiration
- Dec 3, 2029
- Applicant
- Kuraray Medical Inc.
- Claims
- 5
- CPC classes
- A61K, A61K35/12, A61P, A61P3/10
Quick answer
US 7629168 (Insulin expressing human pancreatic islet cell line capable of reversibly proliferating and use thereof) is held by Kuraray Medical Inc.. Status: granted. Granted Dec 8, 2009. Expires Dec 3, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Kuraray Medical Inc.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K35/12, A61P, A61P3/10
More from Kuraray Medical Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12410184
Crystalline forms of a menin inhibitor
granted -
US 12377026
Dental adhesive material kit
granted -
US 12358210
Resin composition for stereolithography
granted -
US 12344691
Resin composition for stereolithography
granted -
US 12214061
Adhesive composition for dental use
granted -
US 12208148
Dental restorative curable composition
granted -
US 12145888
Zirconia molded body and pre-sintered body capable of being sintered in short time
granted -
US 12138325
Dental composition
granted
Frequently asked questions
What is US patent 7629168?
US 7629168 (Insulin expressing human pancreatic islet cell line capable of reversibly proliferating and use thereof) is held by Kuraray Medical Inc.. Status: granted. Granted Dec 8, 2009. Expires Dec 3, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7629168?
Kuraray Medical Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 132 pharmaceutical patents for this assignee.
When does US 7629168 expire?
Our index shows an expiration date of Dec 3, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.